Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
US-9637484-B2 · May 2, 2017 · US
Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
US11261199B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11261199-B2 |
| Application number | US-202016818388-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 13, 2020 |
| Priority date | Oct 5, 2015 |
| Publication date | Mar 1, 2022 |
| Grant date | Mar 1, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from: or a pharmaceutically acceptable salt, enantiomer, racemate, mixture thereof, or combination thereof. 2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof. 3. A method of treating a neurodegenerative disease comprising administering to a subject in need thereof an effective amount of a compound of claim 1 , or a pharmaceutical composition of claim 2 . 4. The method of claim 3 , wherein the neurodegenerative disease is a tauopathy. 5. The method of claim 3 , wherein the neurodegenerative disease is Alzheimer's disease. 6. A method of enhancing autophagic reflux comprising providing to a cell or a protein aggregate an effective amount of a compound of claim 1 , or a pharmaceutical composition of claim 2 . 7. A method of treating a proteinopathy comprising administering to a subject in need thereof an effective amount of a compound of claim 1 , or a pharmaceutical composition of claim 2 . 8. A method of treating a tauopathy comprising administering to a subject in need thereof an effective amount of a compound of claim 1 , or a pharmaceutical composition of claim 2 . 9. A method of treating a neurodegenerative disease comprising administering to a subject in need thereof an effective amount of a compound having the following structure: or a pharmaceutical composition thereof. 10. The method of claim 9 , wherein the neurodegenerative disease is a tauopathy. 11. The method of claim 9 , wherein the neurodegenerative disease is Alzheimer's disease. 12. A method of enhancing autophagic reflux comprising providing to a cell or a protein aggregate an effective amount of a compound having the following structure: or a pharmaceutical composition thereof. 13. A method of treating a proteinopathy comprising administering to a subject in need thereof an effective amount of a compound having the following structure: or a pharmaceutical composition thereof. 14. A method of treating a tauopathy comprising administering to a subject in need thereof an effective amount of a compound having the following structure: or a pharmaceutical composition thereof.
Assignees
Inventors
Classifications
- C07D513/04Primary
Ortho-condensed systems · CPC title
Ortho-condensed systems · CPC title
the oxygen-containing ring being five-membered · CPC title
Ortho-condensed systems · CPC title
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11261199B2 cover?
- The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
- Who is the assignee on this patent?
- Univ Columbia, Ny State Psychiatric Inst
- What technology area does this patent fall under?
- Primary CPC classification C07D513/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).